The Daniel W. Chan Clinical Chemistry Fund
Support a Fellow in Clinical Chemistry
The Daniel W. Chan Clinical Chemistry Fund is an endowed fund established in the Department of Pathology in 2012 to honor Daniel W. Chan, Ph.D., Professor of Pathology and Director of the Division of Clinical Chemistry. The income from the fund supports a fellow in the Division of Clinical Chemistry.
Dr. Chan received his bachelor’s degree in biology from the University of Oregon and his doctoral degree in biochemistry from the State University of New York at Buffalo (SUNY-Buffalo). Following graduation, he completed a year of postdoctoral training in clinical chemistry at SUNY-Buffalo and the Erie County Laboratories at the Meyer Hospital in Buffalo. Dr. Chan then joined the Johns Hopkins Department of Pathology in 1977 as an assistant professor. Just four years later, he was named Director of the Division of Clinical Chemistry, a role he has held with distinction for more than 40 years. Promoted to full professor in 1999, Dr. Chan also holds appointments in the Departments of Oncology, Urology, and Radiology. He has held numerous leadership roles in the Department of Pathology during his tenure. Currently, he also serves as Co-Director of the Pathology Core Laboratories and as founding Director of the Johns Hopkins Center for Biomarker Discovery and Translation.
The focus of Dr. Chan's research is the development and application of proteomic, mass spectrometry and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, molecular diagnostics, and biochemical tumor markers—particularly prostate and ovarian cancer biomarkers. He developed the OVA1 blood test for ovarian cancer which, in 2009, became the first proteomic in vitro diagnostic multivariate index assay cleared by the United State Food and Drug Administration for use in detection of ovarian cancer in women with pelvic masses. For the last 15 years, Dr. Chan has been the principal investigator for both the Biomarker Reference Laboratory for the National Cancer Institute (NCI) Early Detection Research Network and the Proteome Characterization Center of the NCI Clinical Proteomic Tumor Analysis Consortium. The aim of proteogenomic research is to better understand the molecular basis of cancer through the application of mass spectrometry for global proteomic and post-translational modifications analyses.
Over the past two decades, Dr. Chan has given more than 200 invited lectures to both national and international audiences. He has authored five books, 40 book chapters, and more than 300 scientific articles. He holds 12 U.S. patents relating to biomarkers and cancer diagnostics, and has received more than 20 awards for his contributions to clinical chemistry, medicine, and clinical laboratory science. Dr. Chan is a diplomat of the American Board of Clinical Chemistry and a fellow of the National Academy of Clinical Biochemistry (NACB). He has served as Chair of the Proteomics Division of the American Association for Clinical Chemistry, as a member of the Board of Directors of the NACB, and as President of the National Registry in Clinical Chemistry. He also served as President of the International Society of Enzymology, and is a founding member and director of the United States Human Proteome Organization. He serves as the Editor-in-Chief of the journal Clinical Proteomics.
During his long and distinguished tenure at Johns Hopkins, Dr. Chan has trained countless residents and medical students, and has mentored more than 30 clinical chemistry fellows—many of whom have become leaders in the field of clinical chemistry. If you would like to honor Dr. Chan’s remarkable career, please consider making a tax-deductible contribution to the Daniel W. Chan Clinical Chemistry Fund through the Department of Pathology’s secure online giving form by clicking the button below.
Support Now